Alnylam Pharmaceuticals | ALNY - Equity Capital And Reserves


Alnylam Pharmaceuticals reported $1.35B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Moderna USD 6.76B 647M Jun/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Novartis USD 38.93B 7.2B Mar/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 73.14B 1.43B Mar/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Takeda JPY 7.56T 215.7B Jun/2026
Tectonic Therapeutic USD 230.42M 20.91M Mar/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026
Xencor USD 503.23M 12.4M Jun/2026